Apollomics (APLM) Competitors $6.89 -0.71 (-9.34%) Closing price 02/21/2025 03:58 PM EasternExtended Trading$7.04 +0.15 (+2.10%) As of 02/21/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends APLM vs. IXHL, RLYB, PMN, CVM, MRNS, COEP, AKTX, NKGN, PULM, and CMMBShould you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include Incannex Healthcare (IXHL), Rallybio (RLYB), ProMIS Neurosciences (PMN), CEL-SCI (CVM), Marinus Pharmaceuticals (MRNS), Coeptis Therapeutics (COEP), Akari Therapeutics (AKTX), NKGen Biotech (NKGN), Pulmatrix (PULM), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry. Apollomics vs. Incannex Healthcare Rallybio ProMIS Neurosciences CEL-SCI Marinus Pharmaceuticals Coeptis Therapeutics Akari Therapeutics NKGen Biotech Pulmatrix Chemomab Therapeutics Apollomics (NASDAQ:APLM) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk. Which has better valuation & earnings, APLM or IXHL? Incannex Healthcare has lower revenue, but higher earnings than Apollomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApollomics$1.22M6.16-$172.60MN/AN/AIncannex Healthcare$10K2,875.46-$18.46M-$1.39-1.16 Which has more volatility and risk, APLM or IXHL? Apollomics has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Incannex Healthcare has a beta of 7.44, suggesting that its share price is 644% more volatile than the S&P 500. Do analysts rate APLM or IXHL? Apollomics currently has a consensus target price of $200.00, suggesting a potential upside of 2,802.76%. Given Apollomics' stronger consensus rating and higher probable upside, research analysts clearly believe Apollomics is more favorable than Incannex Healthcare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Incannex Healthcare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor APLM or IXHL? In the previous week, Incannex Healthcare's average media sentiment score of 0.68 beat Apollomics' score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the news media. Company Overall Sentiment Apollomics Neutral Incannex Healthcare Positive Is APLM or IXHL more profitable? Apollomics' return on equity of 0.00% beat Incannex Healthcare's return on equity.Company Net Margins Return on Equity Return on Assets ApollomicsN/A N/A N/A Incannex Healthcare N/A -289.30%-154.96% Does the MarketBeat Community believe in APLM or IXHL? Apollomics received 4 more outperform votes than Incannex Healthcare when rated by MarketBeat users. CompanyUnderperformOutperformApollomicsOutperform Votes480.00% Underperform Votes120.00% Incannex HealthcareN/AN/A Do insiders and institutionals have more ownership in APLM or IXHL? 19.1% of Apollomics shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 26.5% of Incannex Healthcare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryApollomics beats Incannex Healthcare on 8 of the 13 factors compared between the two stocks. Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLM vs. The Competition Export to ExcelMetricApollomicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.51M$7.07B$5.81B$9.02BDividend YieldN/A2.77%4.77%3.84%P/E RatioN/A3.9221.5016.68Price / Sales6.16314.28453.1985.13Price / CashN/A67.8343.9637.32Price / Book0.156.757.654.65Net Income-$172.60M$138.11M$3.18B$245.69M7 Day Performance-4.57%-2.54%-1.95%-2.67%1 Month Performance-28.97%-2.00%-0.23%-2.16%1 Year Performance-89.54%-5.04%16.69%12.90% Apollomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLMApollomics2.4397 of 5 stars$6.89-9.3%$200.00+2,802.8%-89.7%$8.26M$1.22M0.0045Gap DownIXHLIncannex Healthcare0.5417 of 5 stars$1.78-1.0%N/A-74.4%$31.41M$86,000.00-1.283Earnings ReportRLYBRallybio2.4536 of 5 stars$0.75-4.0%$9.75+1,194.0%-58.1%$31.26M$598,000.00-0.4740PMNProMIS Neurosciences0.3443 of 5 stars$0.95-0.7%N/A-62.4%$31.06MN/A-9.505News CoverageCVMCEL-SCIN/A$0.42+2.9%N/A-81.5%$30.90MN/A-0.8243News CoverageMRNSMarinus Pharmaceuticals4.2119 of 5 stars$0.55-0.2%$4.79+771.6%-94.4%$30.32M$30.99M-0.22110Analyst ForecastCOEPCoeptis Therapeutics0.546 of 5 stars$12.45+0.9%N/A+7.5%$29.88MN/A-2.152News CoverageAKTXAkari TherapeuticsN/A$1.08-0.3%N/A-58.6%$28.69MN/A0.009Analyst ForecastNews CoverageGap DownNKGNNKGen BiotechN/A$0.63-17.9%N/A-40.1%$28.36M$80,000.00-0.12N/ANews CoverageGap UpHigh Trading VolumePULMPulmatrix0.0789 of 5 stars$7.73+3.2%N/A+404.0%$28.21M$7.30M-2.9320CMMBChemomab Therapeutics2.9666 of 5 stars$1.96-1.0%$7.50+282.7%+153.0%$28.14MN/A-1.9620Analyst ForecastNews Coverage Related Companies and Tools Related Companies Incannex Healthcare Competitors Rallybio Competitors ProMIS Neurosciences Competitors CEL-SCI Competitors Marinus Pharmaceuticals Competitors Coeptis Therapeutics Competitors Akari Therapeutics Competitors NKGen Biotech Competitors Pulmatrix Competitors Chemomab Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APLM) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
